CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 62 enrolled
Drug / intervention
Cisplatin +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02392637
NCT02392637Phase 2Completed

A Phase II Study of Gemcitabine, Cisplatin, and Abraxane in Advanced Biliary Cancers

M.D. Anderson Cancer Center·interventional·Posted Mar 19, 2015·Updated Feb 2, 2022

In Brief

A Phase 2 clinical trial evaluating Cisplatin, Gemcitabine Hydrochloride, and 2 other interventions for Stage III Intrahepatic Cholangiocarcinoma AJCC v7 and 8 related conditions. Completed, enrolled 62 participants across 3 sites.

Detailed Summary

This phase II trial studies how well gemcitabine hydrochloride, cisplatin, and nab-paclitaxel (paclitaxel albumin-stabilized nanoparticle formulation) work in treating patients with biliary cancers (which includes the gallbladder and bile ducts inside and outside the liver) that have spread to other places in the body and usually cannot be cured or controlled with treatment. Drugs used in chemotherapy, such as gemcitabine hydrochloride, cisplatin, and paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination chemotherapy) may kill more tumor cells.

Study Details

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMar 19, 2015
Enrollment StartApr 2, 2015
Primary CompletionAug 13, 2020
TodayJul 2, 2026
Enrollment to primary: 5.4 yearsPosted 11.3 years ago

Interventions

Cisplatindrug

Given IV

Gemcitabine Hydrochloridedrug

Given IV

Laboratory Biomarker Analysisother

Correlative studies

Nab-paclitaxeldrug

Given IV